The PFAS-Free Pivot: How TekniPlex is Reshaping Pharma Packaging

WAYNE, PA – September 29, 2026 – The materials that protect and deliver our most critical medicines are undergoing a quiet but profound revolution. For decades, the pharmaceutical industry has relied on a standard playbook of legacy materials—fluoropolymers for moisture barriers, glass for injectables, and talc or silicone for dispensing mechanisms. Today, a convergence of intense regulatory scrutiny, evolving biologic therapies, and a massive shift toward at-home patient care is rendering that playbook obsolete.

At the upcoming CPHI Milan 2026 exhibition, running from October 6 to 8, TekniPlex Healthcare is positioning itself at the forefront of this transition. The company’s planned showcase reveals a strategic pivot away from legacy components, offering a clear diagnosis of where the global competitive environment is heading. Built around the theme "Protect the Therapy. Enable the Delivery. Advance the Care," the division’s latest material science innovations underscore a critical reality: modern therapies are too sensitive, and environmental regulations too strict, for yesterday's packaging.

"Pharmaceutical innovation increasingly requires materials to do more from protecting highly sensitive therapies to enabling entirely new ways of delivering them," said Brenda Chamulak, CEO of TekniPlex. "At CPHI Milan, we are demonstrating how TekniPlex Healthcare brings material science, manufacturing expertise and application knowledge together to help our customers address these evolving requirements."

The PFAS-Free Packaging Race: Pharma's Rush to Replace Fluoropolymers

Perhaps the most significant headwind facing pharmaceutical supply chains today is the impending regulatory crackdown on per- and polyfluoroalkyl substances (PFAS). Dubbed "forever chemicals" due to their environmental persistence, PFAS are facing aggressive legislative action globally. The European Union’s REACH regulation proposal, which aims to ban approximately 10,000 PFAS substances, has moved steadily through the European Chemicals Agency’s risk assessment committees throughout 2026. Concurrently, the U.S. Environmental Protection Agency has finalized strict drinking water limits and designated certain PFAS as hazardous substances.

For the pharmaceutical packaging sector, this is a seismic event. The industry has historically relied on polychlorotrifluoroethylene (PCTFE)—a fluoropolymer—to provide the ultimate moisture and oxygen barrier for sensitive oral solid doses and specialized formulations. While the industry has lobbied for exemptions, arguing that polymeric PFAS are non-bioaccumulative, forward-looking manufacturers are already seeking viable exit strategies to ensure business continuity.

Enter Flexapharm SBC, a high-barrier pharmaceutical film technology that will be a centerpiece of the TekniPlex stand in Milan. Engineered specifically for moisture- and oxygen-sensitive therapies, Flexapharm SBC delivers the rigorous protection traditionally associated with PCTFE, but crucially, it is entirely PFAS-free.

Beyond regulatory compliance, the new thermoformable film offers tangible operational efficiencies. Industry analysts note that Flexapharm SBC can be processed and sealed at lower temperatures than conventional alternatives. For contract manufacturing organizations and pharmaceutical giants alike, this translates directly to increased production line efficiency and a reduced energy footprint. Furthermore, its compact structural design requires less raw material, driving down transportation and warehousing costs while significantly shrinking the carbon footprint of the final packaged product.

Enabling the Clinic-to-Home Shift: Polymers Power Wearable Biologics

While regulatory pressures reshape primary packaging, a different dynamic is transforming drug delivery: the decentralization of healthcare. Complex biologic therapies, once confined to hospital clinics and intravenous drips, are increasingly being formulated for subcutaneous, at-home administration. This "clinic-to-home" shift requires highly intuitive, wearable on-body injectors capable of delivering large volumes of high-viscosity drugs over extended periods.

Traditional pre-filled glass syringes and cartridges are ill-suited for this new paradigm. Glass is rigid, prone to shattering, and typically requires silicone oil lubrication—a known catalyst for protein aggregation in sensitive biologics.

To bridge this gap, TekniPlex is introducing an advanced flexible film reservoir technology designed specifically for next-generation wearable liquid drug delivery. By replacing rigid glass with high-barrier, thermoformable polymers, device engineers gain unprecedented design freedom. These reservoirs can be custom-shaped to fit the specific architecture of an ergonomic, low-profile wearable device, maximizing patient comfort and discretion.

Moreover, these thin, lightweight film formats maintain strict barriers against moisture and oxygen ingress without the need for reactive lubricants. As biotech companies continue to pipeline highly sensitive, high-value biologics, the demand for shatter-resistant, biologically inert reservoirs will only accelerate.

Cleaning Up the Assembly Line: Removing Talc and Lubricants

The drive for cleaner materials extends deep into the unseen, micro-components of consumer health dispensing systems. For decades, manufacturers of aerosol and pump dispensers have utilized talc and silicone surface treatments to prevent elastomeric components, such as stem gaskets, from sticking during high-speed automated assembly.

However, these legacy treatments carry significant baggage. Talc has faced intense public and regulatory scrutiny over contamination risks, while silicone migration is a persistent headache for quality assurance teams monitoring extractables and leachables. The United States Pharmacopeia (USP) standards for elastomeric components demand rigorous testing to ensure these lubricants do not interact with or degrade the active pharmaceutical ingredients.

TekniPlex’s response to this operational drag is the ClearCycle+ stem gasket. By engineering a proprietary material that requires absolutely no talc or silicone surface treatment, the company is providing a non-stick alternative that fundamentally cleans up the assembly line. FDA-compliant and highly stable, ClearCycle+ allows manufacturers to meet increasingly stringent purity requirements without sacrificing the rapid line speeds essential for high-volume consumer health products. Removing these additives inherently reduces the risk of batch contamination, streamlining compliance and protecting brand equity.

An Integrated Ecosystem for Ophthalmic Care

The synthesis of barrier protection and precise delivery mechanisms is perhaps most vital in the realm of eye care. Ophthalmic formulations are notoriously sensitive to environmental degradation and require absolute sterility from the filling line through the final drop dispensed by the patient.

At CPHI Milan, TekniPlex will highlight its expanding ophthalmic solutions portfolio, illustrating a comprehensive approach that connects advanced materials with precision components. The company is leveraging its expertise in high-barrier polymers to protect moisture- and oxygen-sensitive eye drops, while simultaneously engineering systems that guarantee sterility during patient use.

This portfolio reflects a broader, ecosystem-level strategy. Rather than simply supplying raw materials, TekniPlex operates as a comprehensive contract development and manufacturing partner. By integrating research and development support, material selection, and final component assembly, the company is positioning itself as a single-source partner for pharmaceutical brands navigating the complex regulatory and formulation hurdles of modern eye care. In an industry where the margin for error is microscopic, this holistic oversight of the supply chain offers a critical competitive advantage.